Statistics from Altmetric.com
How effective and safe is citalopram treatment for reducing repetitive behaviour in children and adolescents with autistic spectrum disorders?
149 participants aged 5–17 years who met DSM-IV-TR criteria for autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified, as determined by an experienced clinician (median age 9 years, 73% male, 49% with non-verbal IQ above 70). Eligible participants had to have an illness severity rating of at least moderate on the Clinical Global Impressions (CGI) Severity of Illness scale and at least a moderate score (>8) on the Children's Yale-Brown Obsessive Compulsive Scale for Pervasive Developmental Disorders (CYBOCS-PDD). Anyone taking concomitant medication for psychotropic conditions or medication known to interact with citalopram was excluded.
Six academic medical centres in the USA; recruitment April 2004–October 2006.
Citalopram (10 mg/5 ml, in liquid form) or placebo for 12 weeks. All participants started with 2.5 mg/day citalopram which was increased daily, biweekly or weekly depending on weight, to a possible maximum dose of 20 mg/day. These doses were continued until the CGI improvement (CGI-I) scale was rated as improved or above, but reduced if a dose limiting adverse effect was …
Sources of funding National Institutes of Health.
Competing interests none
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.